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Abstract
The development of antiviral drug resistance is an important problem in the treatment of human immunodeficiency virus type 1 (HIV-1)
infection. Potent antiretroviral therapy (ART) is currently used for treatment, and typically consists of at least two reverse transcriptase (RT)
inhibitors. To assess the impact of combination therapy on HIV-1 mutagenesis, the mutagenic outcome of combined drug treatment was
determined with several different RT drug combinations. Significant increases in HIV-1 mutant frequencies were observed with combi-
nations of nucleoside RT inhibitors as well as in combinations where nucleoside inhibitors were used along with hydroxyurea, a drug known
to deplete nucleotide pools in cells. This indicates that combinations of RT drugs can act together to further increase HIV-1 mutant
frequencies, which could have important implications for virus population dynamics and could compromise drug therapy regimens.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
The treatment of human immunodeficiency virus type 1
(HIV-1)-infected individuals with antiretroviral drugs in-
cluding reverse transcriptase (RT) and protease inhibitors in
a combination therapy (called potent antiretroviral therapy,
or ART) has significantly reduced the rate of HIV and
AIDS-related morbidity and mortality (Richman, 2001).
However, a problem with these therapies is that they can be
suboptimal, due in some cases to a lack of patient compli-
ance to drug administration, and allow for the selection of
drug-resistant viruses (Bangsberg et al., 2000). Antiviral
drugs have been shown to increase virus mutant frequencies
of retroviruses and RNA viruses (Mansky and Bernard,
2000; Mansky and Cunningham, 2000). Since the in vivo
mutation rate for HIV-1 has been previously determined to
be very high (i.e., 4  105 mutations per target bp per
replication cycle) (Mansky, 1996; Mansky and Temin,
1995), the increased virus mutant frequency in the presence
of the drugs could lead to a rapid rate of selection and
fixation of mutations that confer drug resistance (Richman
et al., 1994; Schuurman et al., 1995). These drug-resistant
viruses can readily reside in latently infected cells, which
further complicates subsequent drug treatment regimens
during the life of the infected individual. When drug-resis-
tance mutations accumulate, drug susceptibility diminishes
and reduces the potency of the components of ART. The
continued replication in the presence of drug will select for
even greater levels of resistance and typically leads to cross-
resistance to drugs of the same class. Transmission of
HIV-1 with reduced susceptibility to antiretroviral drugs
may further compromise the efficacy of drug therapy (Gar-
cia-Lerma et al., 2001). In this study, the mutagenic out-
come of various drug combinations on HIV-1 replication
was analyzed. It was found that virus replication in the
presence of nucleoside reverse transcriptase inhibitors
(NRTIs) combinations led to an additive increase in virus
mutant frequencies. Virus replication in the presence of
drug combinations consisting of an NRTI and hydroxyurea,
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a drug known to deplete dNTP pools in cells, also increased
virus mutant frequencies. This indicates that combination
drug therapy increases HIV-1 mutant frequencies, which
could have important implications for long-term adminis-
tration of anti-HIV chemotherapy.
Results
Dose dependent effect of dd1 on HIV-1 mutant
frequencies
Various concentrations of ddI, ranging from 0.1 M to
0.8 M, were tested for their effects on virus mutant fre-
quencies using a postinfection treatement strategy (see ma-
terials and methods) (Fig. 1). There was a corresponding
increase in virus mutant frequency observed (Fig. 2). This
indicates that ddI influences the virus mutant frequency in a
dose-dependent manner. A dose-dependent relationship be-
tween increased drug concentration and increased virus mu-
tant frequency has been previously observed for AZT and
3TC (Mansky and Bernard, 2000), as well as for hydroxy-
urea (Mansky et al., 2002). The maximum increase in virus
mutant frequency in the presence of ddI was 6-fold higher
than the virus mutant frequency during replication in the
absence of the drug (P  0.0001).
Additive effect of NRTI combinations on HIV-1 mutant
frequencies
Various combinations of NRTIs were tested for their
ability to interact together to alter HIV-1 mutant frequencies
during virus replication in a manner that was significantly
different than observed with individual drugs alone. The
drug combinations tested included AZT and 3TC, AZT and
ddI, and finally 3TC and ddI. The rationale for testing these
combinations was that at least two of these NRTIs are
typically used in ART. Control experiments were done with
each drug individually to assess the potential interplay be-
tween drug combinations in altering virus mutant frequen-
cies. Since each drug individually increased the odds of
virus mutants (Fig. 3), it was hypothesized that combined
drug treatments would further increase these odds and result
in an increase of virus mutant frequencies. Several different
outcomes could be envisioned. The drugs could act in an
additive manner, a multiplicative manner, or a synergistic
manner. In each of the NRTI combinations tested, an addi-
tive increase in virus mutant frequencies was observed (Fig.
Fig. 1. Assay system used to analyze virus mutant frequencies in vivo during one round of HIV-1 replication using the lacZ gene as a mutation target. A.
HIV-1 vector used to measure virus mutant frequencies. The proviral DNA form of the vector is shown. The large black rectangular boxes are the long
terminal repeats. The small gray box is the SV40 promoter. The lacZ gene, internal ribosomal entry site (IRES) sequence, and the neo gene are indicated.
B. Single-cycle replication assay for mutant frequencies. HeLa cell clones with single integrated vector proviruses were transiently transfected with helper
plasmids and the produced virus was used to infect fresh HeLa cells that were treated with drug postinfection (see materials and methods). G418-resistant
cells resulting from virus infection of fresh HeLa cells were selected and cells were then stained with X-gal. The ratio of white plus light-blue stained colonies
to total colonies was used to determine the forward mutant frequency.
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3). In particular, virus replication in the presence of AZT or
ddI alone led to 4-fold and 2.8-fold increases in the odds of
recovering virus mutants, respectively. However, during
HIV-1 replication in the presence of both AZT and ddI, the
virus mutant frequency was 6.5-fold higher than observed in
the absence of drug. This 6.5-fold increase in mutant fre-
quency best fits an additive model (i.e., 4  2.8  6.8)
versus that of a multiplicative model (i.e., 4  2.8  11.2)
or a synergistic model (significantly higher than 11.2-fold).
As with the AZT/ddI combination, the combination of 3TC
Fig. 2. Dose-dependent effect of ddI on HIV-1 mutant frequencies. Various concentrations of ddI were analyzed for their influence on HIV-1 replication in
one round of replication. Mutant frequencies were determined as described in Fig. 1. The average mutant frequencies (0.15 mutant/cycle at 0 M ddI) were
determined from 3 replicate experiments  SD.
Fig. 3. Additive effect of nucleoside reverse transcriptase inhibitor (NRTI) combinations on HIV-1 mutant frequencies. Various combinations of NRTIs were
analyzed for their influence on HIV-1 replication in one round of replication. The average mutant frequencies (0.14 mutant/cycle for no drug) were determined
from 3 replicate experiments  SD.
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and ddI also led to an increase in the virus mutant frequency
(i.e., 5-fold) that best fits an additive model (i.e., 2  2.8 
4.8), rather than a multiplicative model (i.e., 2 2.8 5.6),
or a synergistic model (significantly higher than 5.6-fold).
The results with combined AZT and 3TC dual treatment led
to a 6-fold increase in the odds of recovering virus mutants,
which best fits an additive model (i.e., 4  2  6).
Effect of NRTIs and hydroxyurea on HIV-1 mutant
frequencies
Hydroxyurea has been previously shown to inhibit
HIV-1 replication, alter nucleotide pools, and increase
HIV-1 mutant frequencies (Julias and Pathak, 1998; Lori et
al., 1997; Mansky et al., 2002; Meyerhans et al., 1994).
Studies have indicated that combinations of hydroxyurea
and one NRTI can be effective in inhibiting HIV-1 replica-
tion (Biron et al., 1996). In particular, ddI and hydroxyurea
could be a relatively inexpensive alternative to ART for
treatment of HIV-1 infection in underdeveloped countries.
The potential interplay between various NRTIs with hy-
droxyurea on HIV-1 mutant frequencies was analyzed.
Based upon the effects of the individual drugs on virus
mutant frequencies and infectivities, a hydroxyurea concen-
tration of 0.5 mM was used along with a 0.05 M concen-
tration of either AZT, 3TC, or ddI. For each drug alone,
these concentrations had no significant effect on HIV-1
mutant frequencies (Fig. 4). However, when 0.5 mM hy-
droxyurea was combined with either 0.05 M AZT or 0.05
M 3TC, the resulting virus mutant frequencies were 3.5-
fold higher than the virus mutant frequency observed during
virus replication in the absence of drug. Furthermore, the
combination of 0.5 mM hydroxyurea with 0.05 M ddI
resulted in a 6-fold increase in the virus mutant frequency.
Since the drug concentrations used had no effect on the
virus mutant frequency alone, the significant changes in the
virus mutant frequency from replication in the presence of
the different drug combinations was not likely due to addi-
tive or multiplicative effects. Therefore, the observed in-
creases in the virus mutant frequency observed with com-
binations of hydroxyurea and either AZT, 3TC or ddI may
be best described with a synergistic model. Further experi-
ments will verify what model is the most appropriate for
describing these drug interactions on HIV-1 mutant fre-
quencies.
Discussion
This is the first report of antiretroviral drugs acting to-
gether to increase HIV-1 mutant frequencies. The mecha-
nisms for how combinations of NRTIs or one NRTI and
hydroxyurea increase virus mutant frequencies are currently
being investigated. Hypotheses proposed to explain these
increased mutant frequencies include: 1) The drugs alter
nucleotide pools; 2) The drugs are incorporated into plus-
strand DNA and may result in discontinuous DNA synthesis
of viral DNAs with proper ends that integrate with subse-
quent error-prone repair by the host cell; and 3) The drugs
Fig. 4. Effect of nucleoside reverse transcriptase inhibitors and hydroxyurea on HIV-1 mutant frequencies. Various NRTIs were analyzed along with
hydoxyurea for their combined influence on HIV-1 replication in one round of replication. The average mutant frequencies (0.15 mutant/cycle for no drug)
were determined from 3 replicate experiments  SD.
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may noncatalytically bind to RT and cause a conformational
change that influences enzyme fidelity (Julias et al., 1997).
Hydroxyurea is a well-documented drug that alters in-
tracellular dNTP pools. Hydroxyurea alters dNTP pools by
inhibiting ribonucleotide reductase and depleting all dNTPs
and may also influence DNA repair by increasing the sen-
sitivity of cells to UV irradiation and to other mutagens. The
data presented in this report suggest that hydroxyurea can
increase the odds of virus mutants during virus replication
in the presence of hydroxyurea and an NRTI by dNTP pool
depletion. This is presently being further investigated. There
is an interest in using combination therapy of hydoxyurea
and ddI as an inexpensive treatment for HIV-1 infection that
could be more widely used than other more expensive drug
combinations in underdeveloped countries. The data pre-
sented here suggest that the higher virus mutant frequencies
could increase the odds of the selection of drug-resistant
viruses and the evolution of drug resistance. Studies to test
this hypothesis are currently in progress. The effect of
NRTIs on nucleotide pools has not been extensively studied
in different cell lines or in primary lymphocytes and mac-
rophages. It is plausible that these drugs, as well as hy-
droxyurea, could also influence nucleotide pools in partic-
ular cell types. Nucleotide pools are believed to be lower in
nondividing cells such as macrophages, so the effects de-
scribed in this report could be greater in macrophages.
Depletion of dNTP pools by hydroxyurea could also in-
crease the uptake and phosphorylation of NRTIs by a pos-
itive feedback of the nucleoside salvage pathways.
The impact of an altered virus mutation rate on HIV-1
diversity is dependent on size of the virus population. De-
terministic models have been used for predicting the effects
of mutation and selection on HIV-1 populations (Coffin,
1995; Preston, 1997), while stochastic models have been
suggested as being more appropriate (Leigh Brown, 1997).
For HIV-1 replication in solid lymphoid tissue, a simple
metapopulation model for HIV-1 replication shows that the
combination of founder effects and subpopulation turnover
can result in an effective population size much lower than
the actual population size (Frost et al., 2001). This lower
population size could contribute to genetic drift being im-
portant in HIV-1 evolution despite a large number of in-
fected cells. The mutagenic outcome of anti-HIV chemo-
therapy would be predicted to be significant in solid tissue.
Materials and methods
Retroviral vectors and expression plasmids
The expression cassette in the HIV vector used in these
studies is shown in Fig. 1A. The vector cassette containing
the lacZ gene, an internal ribosomal entry site (IRES) ele-
ment, and the neomycin phosphotransferase gene (neo) was
introduced into pGEM NL4-3 (full length molecular clone
of NL4-3) to create pHIVLacZ-IRES-neo. In order to pro-
duce vector virus, the HIV vector was complemented in
trans with a HIV-1 gag-pol expression plasmid, an ampho-
tropic murine leukemia virus env expression plasmid, and a
Vpr expression plasmid derived from pAS1B (Mansky et
al., 2000).
Transfections, infections, and cocultivations
The COS-1 and HeLa cell lines used were obtained from
the American Type Culture Collection (Rockville, MD) and
were maintained in Dulbecco’s modified Eagle’s medium
containing 10% calf serum or 10% fetal bovine serum,
respectively. HIV-1 vector and expression plasmids were
transfected into HeLa cells by using Superfect (Qiagen).
HeLa cells were infected in the presence of Polybrene.
Infection of HeLa target cells was also done by cocultiva-
tion of virus-producing cells with target cells.
The influence of the antiretroviral drugs on HIV-1 mu-
tant frequencies was determined by postinfection treatment
of cells with drug. Postinfection treatment refers to main-
taining HeLa target cells in medium supplemented with
drug for 2 h before cocultivation and continued until 24 h
after cocultivation. Postinfection treatment with drug influ-
ences the HIV-1 mutant frequency only during reverse tran-
scription (Mansky and Bernard, 2000).
Experimental protocol for generating a single round
HIV-1 vector replication
The experimental protocol developed to generate a single
round of HIV-1 vector replication is shown in Fig. 1B. In
this protocol, HeLa cells containing the HIV vector provirus
were created by transiently tranfecting the HIV vector and
helper plasmids into COS-1 cells, harvesting virus 2 days
posttransfection, and infecting HeLa cells. G418-resistant
clones were isolated and characterized for the presence of
single proviruses. The cells were also stained with X-gal to
ensure that no mutations had occurred in the lacZ gene.
Selected clones were then used to generate a single round of
HIV-1 vector replication. HeLa cell clones with single in-
tegrated proviruses were transiently transfected with helper
plasmids and were treated with mitomycin C 48 h posttrans-
fection, and then mixed with fresh HeLa cells. G418-resis-
tant cells resulting from virus infection of fresh HeLa cells
were selected and cells were then stained with X-gal. The
ratio of white plus light-blue stained colonies to total colo-
nies observed provided a forward mutant frequency. Cocul-
tivation of virus-producing cells with permissive target cells
was used because it increased the number of infected cells
for analysis of mutant frequencies without influencing the
rate at which mutations occurred during the one round of
replication. In each experiment, similar numbers of colonies
were screened for control and experimental samples. Titers
for control experiments (wt RT in the absence of drug) were
typically 500–1000 CFU per 5  105 target cells.
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